Development of new validated analytical methods for emtricitabine tenofovir disoproxil fumarate cobicistat and elvitegravir and their applicability to marketed formulation Stribild

dc.contributor.guide	Pawar, A. K. M.
dc.coverage.spatial
dc.creator.researcher	Harini, Uppada
dc.date.accessioned	2022-03-29T09:01:00Z
dc.date.available	2022-03-29T09:01:00Z
dc.date.awarded	2019
dc.date.completed	2019
dc.date.registered
dc.description.abstract	None
dc.description.note
dc.format.accompanyingmaterial	None
dc.format.dimensions
dc.format.extent	ix, 219p.
dc.identifier.uri	http://hdl.handle.net/10603/370702
dc.language	English
dc.publisher.institution	Department of Pharmaceutical Sciences
dc.publisher.place	Vishakhapatnam
dc.publisher.university	Andhra University
dc.relation
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Emtricitabine Tenofovir Disoproxil Fumarate Cobicistat and Elvitegravir and Stribild®-Validation studies
dc.subject.keyword	Emtricitabine Tenofovir Disoproxil Fumarate cobicistat and elvitegravir- Validation-Development of new analytical methods.
dc.subject.keyword	HIV Drugs-Emtricitabine Tenofovir Disoproxil Fumarate Cobicistat and Elvitegravir- Applicability with Stribild®(marketed formulation)-validation
dc.subject.keyword	Pharmacology and Pharmacy
dc.subject.keyword	Pharmacology and Toxicology
dc.title	Development of new validated analytical methods for emtricitabine tenofovir disoproxil fumarate cobicistat and elvitegravir and their applicability to marketed formulation Stribild
dc.title.alternative
dc.type.degree	Ph.D.